94341-52-3

Upstream product

• 32752-54-8 4-(bromomethyl)benzophenone 
• 134-84-9 4-Methylbenzophenone 

Downstream Products

• 1079362-32-5 5,7-bis{[1-(4-benzoylbenzyl)-1H-1,2,3-triazol-4-yl]methoxy}-4-methyl-2H-chromen-2-one 
• 1079362-40-5 7,8-bis{[1-(4-benzoylbenzyl)-1H-1,2,3-triazol-4-yl]methoxy}-4-methyl-2H-chromen-2-one 
• 1079362-48-3 N-{[1-(4-benzoylbenzyl)-1H-1,2,3-triazol-4-yl]methyl}-2-(2-oxo-2H-benzo[h]chromen-4-yl)acetamide 
• 1079362-24-5 7-{[1-(4-benzoylbenzyl)-1H-1,2,3-triazol-4-yl]methoxy}-4-methyl-2H-chromen-2-one 
• 1373502-22-7 N-(4-benzoylbenzyl)-6-formamidohexanamide 
• 1373502-23-8 N-(4-benzoylbenzyl)-6-isocyanohexanamide 
• 1373501-75-7 C₄₆H₄₆N₄O₈ 
• 1373501-77-9 C₄₇H₄₈N₄O₈ 
• 1373501-78-0 C₄₈H₅₀N₄O₈ 
• 1373501-80-4 C₄₉H₅₂N₄O₈ 

Relevant academic research and scientific papers

Discovery of novel triazole compounds as selective IL-1β releasement inhibitors

Inflammation and immunity are closely related to the occurrence and development of a variety of immune diseases. Although IL-1β has been identified as a key cytokine in many immune diseases, safe and specific small molecular IL-1β releasement inhibitors a

Development of a Raltegravir-based Photoaffinity-Labeled Probe for Human Immunodeficiency Virus-1 Integrase Capture

Photoaffinity labeling (PAL) is one of the upcoming and powerful tools in the field of molecular recognition. It includes the determination of dynamic parameters, such as the identification and localization of the target protein and the site of drug binding. In this study, a photoaffinity-labeled probe for full-length human immunodeficiency virus-1 integrase (HIV-1 IN) capture was designed and synthesized, following the structure of the FDA-approved drug Raltegravir. This photoprobe was found to retain the HIV IN inhibitory potential in comparison with its parent molecule and demonstrates the ability to label the HIV-1 IN protein. Putative photoprobe/inhibitor binding sites near the catalytic site were then identified after protein digestion coupled to mass and molecular modeling analyses.

ANTIBACTERIAL HYDROPHILIC COMPOUND AND USE THEREOF

The present disclosure provides an antibacterial hydrophilic compound. The antibacterial hydrophilic compound may react, induced by light through a hydrogen abstraction group in the structural formula thereof, with a C—H group and thus bind to a surface of a material having the C—H group (for example, chemical fibers such as polyester, chinlon, and the like; plastics, rubbers, and other similar materials), which can impart a durable antibacterial activity and hydrophilicity to the material. The antibacterial hydrophilic compound has a relatively strong binding force to the surface of the material without damaging the mechanical properties of the raw material. The present disclosure also provides a modified material that is modified by the antibacterial hydrophilic compound.

Antistatic compound, surface treatment method for material, and modified material

The present invention provides an antistatic compound. The antistatic compound is obtained by chemically reacting a compound with the structural formula represented by L1' or L2' with a compound Q', and the compound Q' is one or more of a polyhydroxy compound, a polycarboxy compound and a polysulfonate compound; L1' and L2' are shown in the description; and in the formulas L1' and L2', r is 1 or 2, Y is one of a single bond, the oxygen atom, the sulfur atom, the selenium atom, -C(O)-, -SO2-, -NH- and a C1-3 alkylene group, R1 to R10 and R to R are respectively independently selected from the hydrogen atom, a halogen atom, a monovalent polar group and a substituted or unsubstituted monovalent C1-18 hydrocarbon group, and at least one of the R1 to R10 or R to R reacts with the compound Q' to achieve chemical bonding. The antistatic compound can be combined with -CH- group-containing materials such as polyester and nylon to make the materials have antistatic properties and dyeability without reducing the mechanical properties of the materials.

Sustainable organophosphorus-catalysed Staudinger reduction

A highly efficient and sustainable catalytic Staudinger reduction for the conversion of organic azides to amines in excellent yields has been developed. The reaction displays excellent functional group tolerance to functionalities that are otherwise prone to reduction, such as sulfones, esters, amides, ketones, nitriles, alkenes, and benzyl ethers. The green nature of the reaction is exemplified by the use of PMHS, CPME, and a lack of column chromatography.

Ugi reaction-assisted rapid assembly of affinity-based probes against potential protein tyrosine phosphatases

The multi-component Ugi reaction has been employed to assemble a small library of affinity-based probes (AfBPs) that target potential protein tyrosine phosphatases. The probes showed good labelling of PTP1B and MptpB, and were subsequently used to label endogenous PTP1B in MCF-7 cell lysates.

Synthesis of potentially photoactivatable coumarin derivatives via a 1,3-dipolar cycloaddition

(Chemical Equation Presented) A copper (I)-catalyzed 1,3-dipolar cycloaddition reaction was used to prepare a series of mono and disubstituted 1,2,3-triazolyl-coumarins using a 1,3-cycloaddition ("Click Chemistry"). Starting coumarins were synthesized using classical or modified Pechmann's reaction. The propargyl group was introduced as either propargylether or as a propargylamide. Azides were prepared in a three steps procedure. Cycloaddition products, containing a coumarin and a photoactivatable moiety, were obtained in good yields.

Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus

The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.